Online ISSN: 2515-8260

Keywords : prostate cancer


Dr. M. Mamatha, Dr. Swarnalatha Sripathi, Dr. Rama Devi Pyla, Dr. Jostna Devi Akarapu

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 5, Pages 334-360

Background: Prostate cancer is the second most common cancer in men and the fourth most common cancer overall. 1.4 million new cases of prostate cancer diagnosed in 2020. PSA and Gleason's score (GS) before treatment are important diagnostic and therapeutic indicators. According to studies, GS degrades tumors while PSA is not cancer-specific. The current study studies the relationship between Ki67, GS, and PSA, which is used to grade tumors and predict patient prognosis. Objectives: 1. To study the histopathology of prostate carcinoma and its variants and assign them a Gleason score as per the Gleason grading system. 2.To study Ki-67 immuno expressing in prostate carcinoma. 3. To correlate Ki-67 expression, Gleason scoring, and serum prostate-specific antigen levels in prostate carcinoma, Methods: A retrospective study enrolled 80 prostate cancer patients from Malla reddy Medical College, Hyderabad from November 2019 to April 2021.Each instance received a Gleason score and Ki67 immunohistochemistry. Ki67 expression and Gleason score were found to be related. Results: All 80 patients were diagnosed with acinar/normal adenocarcinoma-WHO. There were 36 patients with moderately-differentiated tumors (45%) , 28 with high grades (35 percent), and 16 with intermediate grades. PSA levels rose as a result of GS. GS and serum PSA levels increased in direct proportion to Ki6l abeling. Conclusion: Ki67 is a novel biomarker linked to tumor grade and pretreatment PSA levels. It can be used as a diagnostic parameter or to replace prognostic factors.

To study immune histochemical expression of CD34 and CD117 in benign and malignant prostaticlesions

Dr. Asha Jyothi. T, Dr. C. Aruna

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 7-20

Methodology:The present study has been conducted at Department of Pathology,

Correlation Between Serum Prostate-Specific Antigen Level With Pathological Grade And Risk Of Bone Metastasis In Prostate Cancer Patients

Alaa Abdel Hamid Fayed; Seham Mohamed El Hagrasy; Abdelmonem Nasreldin Abdelmonem Hamad; Doaa Abdel Rahman Mandour

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 2, Pages 2420-2427

Background: Prostate cancer is most frequently diagnosed cancer of men and bone is the most common site of metastasis. There is a lack of consensus for the selection criteria for bone scan in low-risk patients. Serum prostate-specific antigen (PSA), which is produced by all types of prostate tissue, is one of the most important biomarkers for detecting prostate cancer, guiding decisions about biopsies of the prostate and offering a way to monitor disease progression. Objective: The aim of this study is to correlate between PSA levels at the time of diagnosis, aggressiveness (Gleason score > 7) and bone metastasis of histologically proved prostate cancer patients. Patients and methods: This study was a Cross Sectional retrospective study collected from medical records at cancer registry archive of Clinical Oncology and Nuclear Medicine at Zagazig University Hospital from January 2014 till January 2019 on 86 prostatic cancer patients with bone metastasis Results: Mean PSA was 217.11±92.56 with range of (100.2 – 502.3), <10 was present in 8.1% of cases, 10-20 was present in 19.8%, 20-100 was present in 34.9% and >100 was present in 37.2% of cases. There was significant relation between PSA and orchidectomy (p<0.001), there was high significant relation between bone metastasis, PSA level (p<0.001) and type of PSA level (p<0.001) and there was significant positive correlation between PSA and GS score, bone metastasis, orchidectomy and ADT. Conclusion: There was strong association between the PSA level, tumor aggressiveness 9 Gleason score), and bone metastasis has been identified in patients already diagnosed as cancer prostate.